Iroko Pharmaceuticals’ $140 million debt facility agreement with CRG LP


Walkers acted as British Virgin Islands law counsel for Iroko Pharmaceuticals in relation to its $140 million debt facility agreement with CRG LP. The new debt facility retired an existing debt facility and provided additional working capital for the company.

Iroko Pharmaceuticals, based in Philadelphia, is a global specialty pharmaceutical company focused on developing and commercialising innovative treatment options for responsible pain management. Through a dynamic, collaborative approach, including the use of novel and proprietary technologies, Iroko develops and commercialises products that help patients manage their pain responsibly. Iroko’s goal is to deliver value to patients, health care professionals, and other stakeholders.

Walkers advised with a team led by Neil McDonald (Picture)

Involved fees earner: Neil McDonald – Walkers Global;

Law Firms: Walkers Global;

Clients: Iroko Pharmaceuticals;

Print Friendly, PDF & Email